

Supplementary Table 2 Adherence to the recommended laboratory monitoring tests in the months before and after initiation of the first oral disease-modifying therapy for the treatment of multiple sclerosis.

Number (n) of people included, by oral DMT and time period	Proportion of people with a laboratory test					
	Biochemical liver test ^a		Lymphocyte count		Urinalysis	
	n	%	n	%	n	%
Dimethyl fumarate						
Pre-treatment						
Within 6 months, n=567	518	91.4	531	93.7	438	77.2
On-treatment						
Months 1-6, n=339	302	89.1	305	90.0	253	74.6
Months 7-12, n=197	175	88.8	180	91.4	141	71.6
Fingolimod						
Pre-treatment						
Within 6 months, n=253	222	87.8	231	91.3		NA
On-treatment						
Months 1-3, n=225	138	61.3		NA		NA
Months 4-6, n=206	139	67.5				
Months 7-9, n=192	118	61.5				
Months 10-12, n=167	92	55.1				

Teriflunomide						
Pre-treatment						
Within 6 months, n=196	179	91.3	183	93.4		NA
On-treatment						
Month 1, n=174	70	40.2		NA		NA
Month 2, n=156	64	41.0				
Month 3, n=147	59	40.1				
Month 4, n=131	45	34.4				
Month 5, n=124	39	31.5				
Month 6, n=117	29	24.8				

Key: DMT, disease-modifying therapy

^aMinimum recommendations, for the biochemical liver tests, according to each DMTs product monograph: either ALT or AST for dimethyl fumarate and fingolimod; and for teriflunomide, either ALT or AST pre-treatment, and ALT while on-treatment.

NA – not applicable as the relevant laboratory test was not part of the routine monitoring recommendations.